Perng, P.-S.; Lai, Y.-H.; Lee, P.-H.; Huang, C.-C.; Hsu, H.-H.; Lee, J.-S.
Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. J. Clin. Med. 2022, 11, 1536.
https://doi.org/10.3390/jcm11061536
AMA Style
Perng P-S, Lai Y-H, Lee P-H, Huang C-C, Hsu H-H, Lee J-S.
Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. Journal of Clinical Medicine. 2022; 11(6):1536.
https://doi.org/10.3390/jcm11061536
Chicago/Turabian Style
Perng, Pang-Shuo, Yu-Hsuan Lai, Po-Hsuan Lee, Chi-Chen Huang, Hao-Hsiang Hsu, and Jung-Shun Lee.
2022. "Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma" Journal of Clinical Medicine 11, no. 6: 1536.
https://doi.org/10.3390/jcm11061536
APA Style
Perng, P.-S., Lai, Y.-H., Lee, P.-H., Huang, C.-C., Hsu, H.-H., & Lee, J.-S.
(2022). Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. Journal of Clinical Medicine, 11(6), 1536.
https://doi.org/10.3390/jcm11061536
